GlassScriptPhysician profile
Carol B Nelson
NPI 1003823410
$59,661.97
in general payments reported to CMS, 2019-2025
19 companies · $50K in 2025
The $50K reported for 2025 was more than what 96% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $685 · 2020: $16.96 · 2021: $159 · 2022: $76.23 · 2023: $314 · 2024: $8,013 · 2025: $50K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $52K · Consulting Fee: $3,050 · Food and Beverage: $2,126 · Travel and Lodging: $1,214.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $52,335.00 |
| Consulting Fee | $3,050.00 |
| Food and Beverage | $2,125.77 |
| Travel and Lodging | $1,214.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $31,523.20 | 2022-2025 | |
| Pfizer INC. | $23,068.68 | 2023-2025 | |
| Janssen Biotech, INC. | $3,945.04 | 2025 | |
| Supernus Pharmaceuticals, INC. | $324.31 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $227.16 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $158.97 | 2021 | |
| Alexion Pharmaceuticals, INC. | $92.79 | 2023-2025 | Ultomiris |
| Biohaven Pharmaceutical Holding Company LTD. | $61.88 | 2022 | |
| Allergan, INC. | $44.17 | 2019 | |
| Celgene Corporation | $33.18 | 2023 | Zeposia |
| Lundbeck LLC | $31.78 | 2020-2025 | Vyepti |
| Vertical Pharmaceuticals, LLC | $30.27 | 2019 | |
| Genentech USA, INC. | $25.47 | 2023 | Ocrevus |
| Eisai INC. | $23.45 | 2019 | |
| Amgen INC. | $23.16 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Argenx US, INC. | $17.89 | 2025 | |
| Lilly USA, LLC | $13.13 | 2024 | Emgality, Reyvow |
| Novartis Pharmaceuticals Corporation | $12.04 | 2019 | |
| Janssen Scientific Affairs, LLC | $5.40 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carol Nelson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.